Filing Flows › Retractable Technologies (RVP) › Q1 2025
Retractable Technologies (RVP) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Retractable Technologies (RVP) reported revenue of $8.3M for the first quarter 2025 (Q1 2025), +9% from a year earlier and -9% from the quarter before. Operating margin was -56.4%, net loss $10.5M (126.6% of revenue).
Retractable Technologies, Q1 2025: revenue $8.3M (+9% year over year), operating margin -56.4%, net loss $10.5M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.3M | -9% | +9% |
| Operating profit | −$4.7M | — | — |
| Net earnings | −$10.5M | -378% | — |
| Operating cash flow | −$1.5M | — | — |
What changed
Revenue was $8.3M in Q1 2025, up 9% year over year and down 9% from the previous quarter. Syringes was the largest line at 84% of revenue. Syringes added $580K year over year (up 9%), 83% of the total change. Blood Collection Products declined 33%.
Operating costs exceeded revenue by $4.7M, an operating margin of -56.4%. The fastest-growing cost line was Research & development (+34%). The quarter ended with a net loss of $10.5M, after a profit of $3.8M the previous quarter. Net interest and other expense of $5.5M was the main reason.
Operating cash flow was −$1.5M. Non-cash charges added back $1.9M of depreciation and amortization. Working capital and other items added $7.1M. Capital expenditures of $87K exceeded it, leaving free cash flow of −$1.6M.
Questions
What was Retractable Technologies' revenue in the first quarter 2025?
Retractable Technologies (RVP) reported revenue of $8.3M for the first quarter 2025 (Q1 2025), +9% from a year earlier and -9% from the quarter before.
Was Retractable Technologies profitable in the first quarter 2025?
Operating loss was $4.7M (-56.4% of revenue) and net loss $10.5M.